Carbocisteine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Carbocisteine: From Mucolytic Agent to Bronchitis Management
One-Sentence Summary
Carbocisteine is a well-established mucolytic drug approved in the United Kingdom, Japan, France, and numerous other countries for chronic respiratory conditions characterised by excessive or viscous mucus production, including chronic bronchitis and COPD. The TxGNN model predicts it may be effective for Bronchitis, with 1 clinical trial and 20 publications — including two Cochrane Systematic Reviews and a 2024 meta-analysis — currently supporting this direction. Carbocisteine’s absence from the South African market reflects a SAHPRA registration gap rather than a lack of efficacy evidence, making this an actionable market introduction opportunity with a strong evidentiary foundation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic bronchitis and respiratory disorders with excessive or viscous mucus secretion (mucolytic; approved in UK, Japan, France, and multiple other countries) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 98.77% |
| Evidence Level | L1 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Carbocisteine (S-carboxymethyl-L-cysteine, SCMC) is a mucoregulatory agent whose pharmacological activity rests on at least four complementary, well-described mechanisms. First, it normalises the ratio of MUC5AC to MUC5B mucins secreted by bronchial glands, shifting mucus composition away from the pathologically viscous state seen in chronic bronchitis and making secretions easier to expectorate. Second, it enhances mucociliary transport by restoring ciliary beat frequency and improving mucus clearance rates along the airway epithelium. Third, it scavenges reactive oxygen species (ROS), reducing oxidative-stress-mediated epithelial injury — a key driver of airway remodelling in chronic obstructive conditions. Fourth, it suppresses pro-inflammatory cytokine release, attenuating the chronic low-grade inflammation that underpins recurrent exacerbations. These properties have been demonstrated in SO₂-induced bronchitis rat models, cultured airway epithelium, and clinical studies across multiple decades.
Bronchitis — whether as acute exacerbations or the chronic obstructive form — is defined by exactly the pathological processes carbocisteine is designed to address: mucus gland hyperplasia, goblet cell proliferation, excess viscous secretions, and impaired mucociliary clearance. The mechanistic connection is therefore direct and biologically well-grounded. Carbocisteine’s ability to normalise bronchial glandular output and reduce goblet cell numbers in inflamed airway epithelium addresses the core pathophysiology, not merely the symptomatic surface of the disease.
Crucially, carbocisteine is not a repurposed candidate for bronchitis in the traditional sense — it is already the established first-line mucolytic for this indication in multiple major jurisdictions. The UK MHRA licence for Mucodyne® (carbocisteine oral syrup and capsules) specifically covers chronic bronchitis and COPD. The landmark PEACE trial, conducted in China, demonstrated a 25% reduction in acute exacerbation rates in COPD patients treated with carbocisteine versus placebo. Two Cochrane Systematic Reviews have independently confirmed its efficacy profile. The TxGNN model’s high prediction score (98.77%) accurately reflects this established biological and clinical plausibility. The drug’s absence from South Africa is a regulatory market access gap — its introduction would bring local patients in line with international standards of mucolytic care.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02858193 | Phase 1 | Completed | 30 | Two-way crossover bioequivalence study comparing carbocisteine-L-lysine salt 1.35 g powder for oral solution against the 90 mg/mL syrup formulation in healthy volunteers under fasting conditions. Confirmed equivalent rate (Cmax) and extent (AUC0–t) of carbocisteine absorption between the two formulations. Supports a complete pharmaceutical quality dossier for potential SAHPRA registration of an oral solution formulation. |
Note: The single registered trial retrieved is a Phase 1 formulation study, not an efficacy trial. The primary efficacy and safety evidence for carbocisteine in bronchitis and COPD resides in the published RCT literature and Cochrane Systematic Reviews listed below. The landmark PEACE trial (Zheng et al., 2008, Lancet) — which enrolled 709 COPD patients — is the largest single RCT supporting this indication but was not captured in this Evidence Pack’s retrieval window.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39413571 | 2024 | Systematic Review / Meta-analysis | Respiratory Investigation | Mucolytics in stable COPD patients: demonstrated statistically significant reduction in exacerbation frequency and improvement in health-related quality of life outcomes; carbocisteine included as a primary study drug. Most current high-level evidence available. |
| 31107966 | 2019 | Cochrane Systematic Review | Cochrane Database of Systematic Reviews | Mucolytics vs. placebo for chronic bronchitis/COPD: carbocisteine is one of the principal study drugs. Statistically significant reduction in exacerbation rates, sick days, and healthcare utilisation demonstrated across pooled RCTs. |
| 3907681 | 1985 | RCT (Double-blind, placebo-controlled) | British Journal of Clinical Practice | Long-term oral carbocisteine therapy in chronic bronchitis: confirmed reduction in exacerbation frequency and improvement in sputum characteristics versus placebo over extended follow-up. One of the earliest pivotal trials. |
| 23728642 | 2013 | Cochrane Systematic Review | Cochrane Database of Systematic Reviews | Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Evidence in this specific subgroup was limited; routine use in otherwise healthy children with acute infections not supported. |
| 19160217 | 2009 | Cochrane Systematic Review | Cochrane Database of Systematic Reviews | Earlier version of the paediatric mucolytic Cochrane Review: carbocisteine safety and limited benefit in children without pre-existing chronic lung disease reviewed; informed subsequent guideline recommendations on age-restricted use. |
| 20956182 | 2010 | Narrative Review | European Respiratory Review | Mucoactive therapy in COPD: analysis of meta-analyses covering 26 studies (21 in chronic bronchitis, 5 in COPD). Carbocisteine highlighted as a key agent demonstrating reduced exacerbation risk; associated data on FEV₁ decline and hospitalisation reviewed. |
| 3155012 | 1988 | Clinical Trial | Archivio Monaldi | Carbocisteine–sobrerol combination versus placebo in acute exacerbations of chronic bronchitis: improved clinical outcomes including reduction in duration and severity of exacerbations and purulent sputum production. |
| 30670922 | 2019 | Narrative Review | Clinical Medicine Insights: ENT | Mucoactive agents for upper and lower respiratory tract infections: carbocysteine reviewed alongside ambroxol, bromhexine, NAC, and erdosteine. Confirmed well-established regulatory status across multiple jurisdictions and outlined appropriate clinical use boundaries. |
| 18832259 | 2008 | Comparative Review | Drug and Therapeutics Bulletin | Erdosteine vs. older mucolytics (carbocisteine, mecysteine) for COPD exacerbations: confirmed carbocisteine’s established long-term prevention role with a well-characterised safety profile versus the newer agent. |
| 23291681 | 2013 | Case Report ⚠️ Safety Alert | Internal Medicine (Tokyo) | Confirmed case of carbocisteine-induced pneumonia (positive drug lymphocyte stimulation test) in a 32-year-old male with CATCH22 syndrome (DiGeorge syndrome) presenting during acute bronchitis treatment. Bilateral ground-glass opacities on chest X-ray; resolved on drug withdrawal. Rare but clinically important adverse event. |
South Africa Market Information
Carbocisteine currently has no SAHPRA-registered products in South Africa. There are no active licences, approved dosage forms, or products available on the South African market.
For reference, carbocisteine is available internationally in the following formulations:
| Formulation | Strength | Example Product | Country |
|---|---|---|---|
| Oral syrup (adult) | 250 mg / 5 mL | Mucodyne® | UK, Japan |
| Oral syrup (paediatric) | 125 mg / 5 mL | Mucodyne Paediatric® | UK |
| Capsules | 375 mg | Various | Europe, Asia |
| Oral solution sachet | 2.7 g carbocisteine-lysine | Rhinathiol® | France, Italy |
A SAHPRA full registration application or, as an interim measure, a Section 21 (unregistered medicines) authorisation would be required before clinical use in South Africa. Note that the bioequivalence data from NCT02858193 supports the pharmaceutical quality dossier for an oral solution formulation.
Safety Considerations
Key safety signal identified in the literature:
- Drug-induced pneumonia (rare): A confirmed case of carbocisteine-induced pneumonia has been documented in a patient with CATCH22 syndrome (DiGeorge syndrome) (PMID 23291681). If a patient develops new or worsening respiratory symptoms, bilateral infiltrates, or fever while taking carbocisteine — paradoxically — drug-induced lung toxicity should be included in the differential diagnosis, particularly in patients with underlying immune deficiencies. Discontinue the drug and arrange urgent respiratory evaluation if suspected.
For comprehensive prescribing information, refer to the UK MHRA-approved Summary of Product Characteristics (SmPC) for Mucodyne® or an equivalent national PI from a jurisdiction where carbocisteine is currently registered, until a SAHPRA-approved Professional Information (PI) document becomes available.
Report adverse drug reactions to SAHPRA via the MedSafety online reporting system.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Carbocisteine carries the strongest evidence level (L1) of all TxGNN predictions in this Evidence Pack, supported by two Cochrane Systematic Reviews, a 2024 meta-analysis, multiple RCTs, and international regulatory approvals across major jurisdictions. The recommendation to “Proceed with Guardrails” reflects not clinical uncertainty, but the practical steps required to bring a well-evidenced, globally-approved drug into the South African market safely and in compliance with SAHPRA requirements.
To proceed, the following is needed:
- SAHPRA registration: Initiate a registration application for an appropriate carbocisteine formulation (oral syrup and/or capsules). Explore Section 21 authorisation as an interim access pathway while the full registration process is underway.
- Professional Information (PI) review: Obtain and review a full SmPC or PI (e.g., Mucodyne® SmPC from the UK MHRA) to formally document local warnings, contraindications, special population guidance, and dosing schedules prior to any patient use.
- Essential Medicines List (EML) assessment: Evaluate carbocisteine for EML inclusion — its demonstrated ability to reduce COPD exacerbations and hospitalisation aligns directly with primary respiratory care priorities under the National Health Insurance (NHI) framework and the public sector formulary.
- Pharmacoeconomic analysis: Compare carbocisteine cost-effectiveness against currently available South African mucolytics (N-acetylcysteine, ambroxol, bromhexine) across relevant patient populations (chronic bronchitis, COPD, ARTI).
- Pharmacovigilance plan: Establish monitoring protocols specifically capturing the rare but documented risk of drug-induced pneumonia (PMID 23291681), with particular vigilance in patients with immunodeficiency conditions.
- Paediatric use guidance: Note that Cochrane evidence (PMIDs 23728642 and 19160217) does not support routine use in children without pre-existing chronic broncho-pulmonary disease for acute infections; local paediatric prescribing guidance should reflect this restriction.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.